Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide

Ip, Eric J.; Lee-Ma, Annette; Troxell, Lawrence S.; Chan, James

doi:10.2146/ajhp070489

Cited by 12 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Note that originator filgrastim is also available in the 480-μg dose for patients weighing Z65 kg; however, the 300-μg dose is the unit of reference commonly cited in last literature. [25][26][27][28][29] …”

Section: Model Designmentioning

confidence: 99%

Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study

Sun

Andayani

Altyar

et al. 2015

Clinical Therapeutics

View full text Add to dashboard Cite

Section: Model Designmentioning

confidence: 99%

Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study

Sun

Andayani

Altyar

et al. 2015

Clinical Therapeutics

View full text Add to dashboard Cite

“…Filgrastim and pegfilgrastim were associated with similar incidences of bone pain in another large analysis (RR 0.95, 95% CI 0.76–1.19) [75]. Although administering a lower-than-recommended dose of G-CSF (pegfilgrastim) was reported to be successful in reducing bone pain [88], this strategy obviously risks achieving suboptimal protection against FN [89], and it is at yet unclear whether bone pain is dose-related.…”

Section: Tolerability Issuesmentioning

confidence: 99%

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Aapro

Crawford

Kamioner³

2010

Support Care Cancer

View full text Add to dashboard Cite

Updated international guidelines published in 2006 have broadened the scope for the use of granulocyte colony-stimulating factor (G-CSF) in supporting delivery of myelosuppressive chemotherapy. G-CSF prophylaxis is now recommended when the overall risk of febrile neutropenia (FN) due to regimen and individual patient factors is ≥20%, for supporting dose-dense and dose-intense chemotherapy and to help maintain dose density where dose reductions have been shown to compromise outcomes. Indeed, there is now a large body of evidence for the efficacy of G-CSFs in supporting dose-dense chemotherapy. Predictive tools that can help target those patients who are most at risk of FN are now becoming available. Recent analyses have shown that, by reducing the risk of FN and chemotherapy dose delays and reductions, G-CSF prophylaxis can potentially enhance survival benefits in patients receiving chemotherapy in curative settings. Accumulating data from ‘real-world’ clinical practice settings indicate that patients often receive abbreviated courses of daily G-CSF and consequently obtain a reduced level of FN protection. A single dose of PEGylated G-CSF (pegfilgrastim) may provide a more effective, as well as a more convenient, alternative to daily G-CSF. Prospective studies are needed to validate the importance of delivering the full dose intensity of standard chemotherapy regimens, with G-CSF support where appropriate, across a range of settings. These studies should also incorporate prospective evaluation of risk stratification for neutropenia and its complications.

show abstract

“…Cyclophosphamide is a cytotoxic nitrogen mustard alkylating agent from the oxazophorines group that has proven efficacy in various human malignancies [1,2]. The clinical usefulness of the anti‐neoplastic agent has been precluded by detrimental toxicities, namely haemorrhagic cystitis [3] and myelosuppression [4].…”

mentioning

confidence: 99%

Uroprotective Effects of Curcumin in Cyclophosphamide‐Induced Haemorrhagic Cystitis Paradigm

Arafa

2009

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Abstract:The possible uroprotective effects of curcumin have been addressed in the current study. Haemorrhagic cystitis was induced by challenging male Swiss albino rats with a single dose of cyclophosphamide (150 mg/kg, i.p.). Curcumin (200 mg/kg, i.p.) was administered for 10 consecutive days followed by a single dose of cyclophosphamide. Haemorrhagic cystitis was well characterized morphologically and biochemically. The hallmark of this toxicity was marked congestion, oedema and extravasation in rat urinary bladder, as well as a marked desquamative damage to the urothelium and severe inflammation in the lamina propria. Leucocytic infiltration was also observed and determined by histopathological examination. Serum level of tumour necrosis factor-alpha was notably elevated associated with apparent hypokalaemia and hyponatraemia. Bladder contents of adenosine triphosphate, reduced glutathione and glutathione-S -transferase activity were markedly reduced. Malondialdehyde level, myeloperoxidase activity and urinary nitrite-nitrate levels, expressed as nitric oxide, were dramatically increased. Prior administration of curcumin ahead of cyclophosphamide challenge improved all the biochemical and histologic alterations induced by the cytotoxic drug. Based on these broad findings, it could be concluded that curcumin has proven uroprotective efficacy in this cyclophosphamide haemorrhagic cystitis model, possibly through modulating the release of inflammatory endocoids, namely tumour necrosis factor-alpha and nitric oxide, improving the energy status and restoring the oxidant/antioxidant balance.

show abstract

Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide

Cited by 12 publications

References 19 publications

Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study

Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Uroprotective Effects of Curcumin in Cyclophosphamide‐Induced Haemorrhagic Cystitis Paradigm

Contact Info

Product

Resources

About